Effect of Second mitochondria-derived activator of caspase in combination with Docetaxel on lung cancer cell A549
Xiao-Mei Li1, Yong-Wei Yang2, Xiao-Kaiti Maimaitiyiming2
1Cancer Center of The Second Hospital, Shandong University Jinan, China.
Abstract:
This study was to investigate inhibiting effect of structurally unique Second mitochondria-derived activator of caspase (Smac) in combination with Docetaxel on lung cancer cell line A549. Results showed that the expression of Smac in transfected A549 cells was higher than the control cells both at mRNA level and protein level (P<0.05). Smac over-expression induced a little apoptosis, however, when treated with Docetaxel together, the cells showed a higher apoptosis rate. The apoptosis rate was significantly increased in Smac + Docetaxel group when compared with that in Smac group and Docetaxel group (P<0.05). Cells cloning ability in Smac + Docetaxel group was worse than that of other groups (P<0.05), cell mass formed in relatively small quantities and sparse location. Thus, over-expression of Smac increases the sensitivity of lung cancer A549 cells to Docetaxel treatment, and transfection of Smac to tumor cells might provide a potential therapy modality.
Insights
Over-expressing Second mitochondria-derived activator of caspase (Smac) enhances lung cancer cell sensitivity to Docetaxel. This combination therapy shows potential for treating A549 lung cancer cells by increasing apoptosis and reducing cell viability.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Lung cancer remains a leading cause of cancer-related mortality worldwide.
- Targeted therapies are crucial for improving treatment outcomes.
- Second mitochondria-derived activator of caspase (Smac) is a protein involved in apoptosis regulation.
Purpose of the Study:
- To investigate the combined inhibitory effect of Smac and Docetaxel on the A549 lung cancer cell line.
- To evaluate the impact of Smac over-expression on Docetaxel-induced apoptosis and cell viability.
Main Methods:
- Transfection of A549 cells to over-express Smac.
- Treatment of cells with Smac, Docetaxel, or a combination of both.
- Assessment of Smac expression at mRNA and protein levels.
- Quantification of apoptosis rates and cell cloning ability.
Main Results:
- Smac over-expression was confirmed at both mRNA and protein levels in transfected A549 cells.
- Combined treatment with Smac and Docetaxel significantly increased the apoptosis rate compared to individual treatments.
- The combination therapy markedly reduced the cells' cloning ability and cell mass formation.
Conclusions:
- Over-expression of Smac sensitizes lung cancer A549 cells to Docetaxel treatment.
- Smac transfection represents a potential therapeutic strategy for lung cancer.
- The synergistic effect of Smac and Docetaxel warrants further investigation for clinical application.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...